Hemab Therapeutics Holdings Inc (COAG)

Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress

New results from HMB-002 first-in-human data validate proof of mechanism in Von Willebrand disease (VWD...

Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 27, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Hemab Therapeutics Reports First Quarter 2026 Financial Results

Completed Initial Public Offering in May 2026, raising gross proceeds of $346.7 million and listing on Nasdaq...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership

Form 8-K - Current report

Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 04, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage...

Hemab Therapeutics Announces Pricing of Upsized Initial Public Offering

CAMBRIDGE, Mass. and COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage...